Head-To-Head Analysis: BioAtla (NASDAQ:BCAB) and Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Vigil Neuroscience and BioAtla’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vigil Neuroscience	N/A	-57.26%	-49.50%
BioAtla	N/A	-110.65%	-75.37%

Earnings & Valuation

This table compares Vigil Neuroscience and BioAtla’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vigil Neuroscience	N/A	N/A	-$82.64 million	($2.13)	-1.27
BioAtla	$250,000.00	488.70	-$123.46 million	($2.59)	-0.98

Vigil Neuroscience has higher earnings, but lower revenue than BioAtla. Vigil Neuroscience is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vigil Neuroscience has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vigil Neuroscience and BioAtla, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vigil Neuroscience	1	0	3	0	2.50
BioAtla	0	0	3	0	3.00

Vigil Neuroscience presently has a consensus price target of $17.40, suggesting a potential upside of 542.07%. BioAtla has a consensus price target of $11.00, suggesting a potential upside of 333.07%. Given Vigil Neuroscience’s higher possible upside, equities analysts plainly believe Vigil Neuroscience is more favorable than BioAtla.

Insider & Institutional Ownership

83.6% of Vigil Neuroscience shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 33.5% of Vigil Neuroscience shares are held by insiders. Comparatively, 8.4% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vigil Neuroscience beats BioAtla on 8 of the 10 factors compared between the two stocks.

About Vigil Neuroscience

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.